Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology
Lung Cancer
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
Lung Cancer Study CASA404A2302
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Phase 2, Open Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients with Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regimen and Failure of Treatment with Erlotinib
A Phase I Study of MM-10-001 In Advanced Non Small Lung Cancer
A Phase I Trial of External Beam Radiotherapy Combined with Carboplatin and Paclitaxel Followed by Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66) in Unresectable or Medically Inoperable Non-Metastatic CEA-Producing Stage III or IIB Non Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Erlotinib (Tarceva) and and Celecoxib (Celebrex) versus Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients
FORTIS-C: A Phase 3, Randomzied, Placebo-Controlled Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel as First-Line Therapy in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer
GEM017: A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin and Radiotherapy followed by Consolidation Pemetrexed v Etoposide, Cisplatin and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III NSCLC Other than Predominantly Squamous Cell Histology
PHII-65 NCI #7103: A Phase II Study of AZD2171 (NSC #732208)in Patients with Malignant Mesothelioma
The Relationship Between Coping, Gender and Psychological Adaptation in People with Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Lung Cancer Study CASA404A2302
Sunitinib, Cisplatin or Carboplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer CALGB 30504
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide CALGB 30610
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
Phase 1, Dose Escalation Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
Randomized, Multi-Center, Open-Label, Study of Docetaxel Versus Docetaxel/PR104 in Non-Small Cell Lung Cancer (NSCLC)
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Lung Cancer Study CASA404A2302
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Cancer: Lung Cancer Patients Needed for Research Study
Cancer: Non-small Cell Lung Cancer Research Study
Cancer: Stage II or III non-small Cell Lung Cancer Research Study
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Lung Cancer Study CASA404A2302
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Lung Cancer Study CASA404A2302
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux®) in Combination with Platinum-Based Chemotherapy as First Line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Pemetrexed in subjects with Stage III/IV NSCLC
Combination Drug Therapy for non-small cell lung cancer not previously treated with chemotherapy
Non-Small Cell Lung Cancer - Adults
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4.0 cm) - IIIA Non Small Cell Lung Cancer (NSCLC)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Lung Cancer Study CASA404A2302
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Phase II Study Of Antineoplaston A10 And AS2-1 Capsules In Patients With Non Small Cell Lung Cancer
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Lung
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Bronchial Alveolar Carcinoma Of The Lung
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Large Cell, Undifferentiated Or Poorly Differentiated Carcinoma Of The Lung
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Small Cell Carcinoma Of The Lung
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Squamous Cell Carcinoma Of The Lung
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer.
Patients with lung cancer needed for clinical study.
Patients with lung cancer wanted for clinical trial
Phase III randomized multi-standard trial of Gemcitabin in combination with Carboplatin or Paclitaxel vs. Paclitaxel plus Carboplatin in patients with metastatic (stage IIIB pleural effusion or IV) non-small cell lung cancer. HIC #8775
Phase III trial of Carboplatin/Paclitaxel and thoracic radiation with or without Thalidomide in patients with stage III non-small cell lung cancer. HIC #8779
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Study CASA404A2302
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients (APRiCOT-L)
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Study of Risk Stratification in Patients With Suspected Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Study of Risk Stratification in Patients With Suspected Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Risk Stratification in Patients With Suspected Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Risk Stratification in Patients With Suspected Lung Cancer.
A Study of Risk Stratification in Patients With Suspected Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
